SCHEMBL1237482

SCHEMBL1237482

Cc1cccc(NC(=O)c2ccc3nc(NC4CCN(C)CC4)n(Cc4nc(C)ccc4O)c3c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACSS2 Q9NR19 1/20 0.41
LCK P06239 5/20 0.40
INSR P06213 3/20 0.40
LYN P07948 3/20 0.40
SRC P12931 3/20 0.40
KDR P35968 3/20 0.40
HCK P08631 1/20 0.40
RAB9A P51151 3/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PIN1 Q13526 1/20 0.38
FLT3 P36888 1/20 0.38
NPC1 O15118 2/20 0.38
MAPK14 Q16539 1/20 0.37
KCNH2 Q12809 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1238612 0.94 NPC1 (0.43) ACSS2LCKINSRLYNSRC
SCHEMBL1237498 0.89 RAB9A (0.49) LCKINSRLYNSRCKDR
SCHEMBL8292649 0.85 KCNH2 (0.46) ACSS2LCKMAPTALDH1A1TP53
SCHEMBL8292653 0.82 DYRK1A (0.41) ACSS2MAPTKDM4EALDH1A1NPC1
SCHEMBL1238600 0.81 SCD (0.40) MAPTKCNH2
SCHEMBL8294929 0.80 KCNH2 (0.41) LCKMAPTALDH1A1TP53SMN1; SMN2
SCHEMBL1238558 0.79 KCNH2 (0.39) LCKMAPTALDH1A1TP53SMN1; SMN2
SCHEMBL8294757 0.79 KCNH2 (0.39) ACSS2LCKMAPTALDH1A1TP53
SCHEMBL8294206 0.78 KCNH2 (0.43) LCKMAPTALDH1A1TP53SMN1; SMN2
SCHEMBL12909078 0.78 KCNH2 (0.43) LCKMAPTALDH1A1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278455-B2 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication JANSSEN PHARMACEUTICA N.V. (BE) 2012-10-02 US disclosed
EP-1697347-B1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARM LTD (IE) 2011-02-23 EP disclosed
US-20090062278-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION JANSSEN SCIENCES IRELAND UC (IE) 2009-03-05 US disclosed
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication BONFANTI JEAN-FRANCOIS 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SUB1, HYOU1 ACSS2 708/4885LCK 4753/4885INSR 3594/4885
US-20090062278-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYC1, SUB1 ACSS2 638/4885LCK 4667/4885INSR 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.